WO2002058718A2 - Use of compositions containing pdgf-bb for promoting angiogenesis - Google Patents
Use of compositions containing pdgf-bb for promoting angiogenesis Download PDFInfo
- Publication number
- WO2002058718A2 WO2002058718A2 PCT/US2002/001666 US0201666W WO02058718A2 WO 2002058718 A2 WO2002058718 A2 WO 2002058718A2 US 0201666 W US0201666 W US 0201666W WO 02058718 A2 WO02058718 A2 WO 02058718A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pdgf
- fgf
- vegf
- angiogenesis
- tissue
- Prior art date
Links
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 55
- 230000001737 promoting effect Effects 0.000 title claims abstract description 21
- 108010081589 Becaplermin Proteins 0.000 title claims description 116
- 239000000203 mixture Substances 0.000 title claims description 10
- 239000002870 angiogenesis inducing agent Substances 0.000 claims abstract description 66
- 238000000034 method Methods 0.000 claims abstract description 58
- 230000006444 vascular growth Effects 0.000 claims abstract description 8
- 239000003094 microcapsule Substances 0.000 claims description 61
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 52
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 47
- 229920002684 Sepharose Polymers 0.000 claims description 43
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 37
- 229920000669 heparin Polymers 0.000 claims description 37
- 229960002897 heparin Drugs 0.000 claims description 37
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 36
- 229940072056 alginate Drugs 0.000 claims description 36
- 235000010443 alginic acid Nutrition 0.000 claims description 36
- 229920000615 alginic acid Polymers 0.000 claims description 36
- 239000013598 vector Substances 0.000 claims description 34
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 25
- 238000002347 injection Methods 0.000 claims description 25
- 239000007924 injection Substances 0.000 claims description 25
- 239000011324 bead Substances 0.000 claims description 24
- 239000000560 biocompatible material Substances 0.000 claims description 21
- 208000028867 ischemia Diseases 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 229920000642 polymer Polymers 0.000 claims description 15
- 210000004204 blood vessel Anatomy 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims description 8
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims description 8
- 230000001177 retroviral effect Effects 0.000 claims description 8
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims description 7
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 claims description 7
- 238000002513 implantation Methods 0.000 claims description 7
- -1 cationic lipid Chemical class 0.000 claims description 6
- 239000010410 layer Substances 0.000 claims description 6
- 108010059616 Activins Proteins 0.000 claims description 5
- 102000009088 Angiopoietin-1 Human genes 0.000 claims description 5
- 108010048154 Angiopoietin-1 Proteins 0.000 claims description 5
- 102000009075 Angiopoietin-2 Human genes 0.000 claims description 5
- 108010048036 Angiopoietin-2 Proteins 0.000 claims description 5
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 5
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 5
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 5
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 5
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 5
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 5
- 101800004490 Endothelin-1 Proteins 0.000 claims description 5
- 108090000394 Erythropoietin Proteins 0.000 claims description 5
- 102000003951 Erythropoietin Human genes 0.000 claims description 5
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 5
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 5
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 5
- 108090000378 Fibroblast growth factor 3 Proteins 0.000 claims description 5
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 claims description 5
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 claims description 5
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims description 5
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 claims description 5
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 claims description 5
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 claims description 5
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 claims description 5
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 claims description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 5
- 102100026818 Inhibin beta E chain Human genes 0.000 claims description 5
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 5
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 5
- 108050009450 Neuropilin Proteins 0.000 claims description 5
- 102000002111 Neuropilin Human genes 0.000 claims description 5
- 108010081689 Osteopontin Proteins 0.000 claims description 5
- 102000004264 Osteopontin Human genes 0.000 claims description 5
- 102100040681 Platelet-derived growth factor C Human genes 0.000 claims description 5
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 claims description 5
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 claims description 5
- 239000000488 activin Substances 0.000 claims description 5
- 229940105423 erythropoietin Drugs 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 108010017843 platelet-derived growth factor A Proteins 0.000 claims description 5
- 108010017992 platelet-derived growth factor C Proteins 0.000 claims description 5
- 102000005162 pleiotrophin Human genes 0.000 claims description 5
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 5
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 4
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 4
- 230000017531 blood circulation Effects 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- XEPXGZZWVKNRGS-GQYPCLOQSA-N n-[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]octanamide Chemical compound CCCCCCCC(=O)NC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XEPXGZZWVKNRGS-GQYPCLOQSA-N 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- SCRCZNMJAVGGEI-UHFFFAOYSA-N 1,4-dioxane-2,5-dione;oxepan-2-one Chemical compound O=C1COC(=O)CO1.O=C1CCCCCO1 SCRCZNMJAVGGEI-UHFFFAOYSA-N 0.000 claims description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 3
- 229920000954 Polyglycolide Polymers 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 229950010732 poliglecaprone Drugs 0.000 claims description 3
- 239000004633 polyglycolic acid Substances 0.000 claims description 3
- 238000003259 recombinant expression Methods 0.000 claims description 3
- 239000002356 single layer Substances 0.000 claims description 3
- 102100033902 Endothelin-1 Human genes 0.000 claims 3
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims 3
- 230000006698 induction Effects 0.000 claims 3
- 101150019331 FGF2 gene Proteins 0.000 claims 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims 2
- 229920000936 Agarose Polymers 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 101150088952 IGF1 gene Proteins 0.000 claims 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 239000005038 ethylene vinyl acetate Substances 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 229920002492 poly(sulfone) Polymers 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 229940078499 tricalcium phosphate Drugs 0.000 claims 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims 1
- 235000019731 tricalcium phosphate Nutrition 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 28
- 108010082117 matrigel Proteins 0.000 description 28
- 230000002491 angiogenic effect Effects 0.000 description 25
- 241000700159 Rattus Species 0.000 description 22
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 22
- 210000004088 microvessel Anatomy 0.000 description 22
- 239000008188 pellet Substances 0.000 description 20
- 239000002775 capsule Substances 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 17
- 239000013613 expression plasmid Substances 0.000 description 16
- 239000003102 growth factor Substances 0.000 description 16
- 210000003098 myoblast Anatomy 0.000 description 15
- 230000003389 potentiating effect Effects 0.000 description 11
- 102000008076 Angiogenic Proteins Human genes 0.000 description 10
- 108010074415 Angiogenic Proteins Proteins 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000003489 abdominal muscle Anatomy 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 210000004087 cornea Anatomy 0.000 description 9
- 230000000302 ischemic effect Effects 0.000 description 9
- 238000011179 visual inspection Methods 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 239000012148 binding buffer Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 7
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 239000005090 green fluorescent protein Substances 0.000 description 7
- 230000004217 heart function Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 208000010125 myocardial infarction Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010061216 Infarction Diseases 0.000 description 6
- 230000003187 abdominal effect Effects 0.000 description 6
- 230000003302 anti-idiotype Effects 0.000 description 6
- 230000007574 infarction Effects 0.000 description 6
- 210000005166 vasculature Anatomy 0.000 description 6
- 230000002861 ventricular Effects 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 241000700605 Viruses Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 206010034576 Peripheral ischaemia Diseases 0.000 description 3
- 230000006427 angiogenic response Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 102400000686 Endothelin-1 Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 2
- 208000021328 arterial occlusion Diseases 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 239000011885 synergistic combination Substances 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000000779 thoracic wall Anatomy 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000004792 Prolene Substances 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 230000026341 positive regulation of angiogenesis Effects 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002559052A JP4434584B2 (en) | 2001-01-26 | 2002-01-18 | Methods and compositions for promoting angiogenesis |
CA002436076A CA2436076A1 (en) | 2001-01-26 | 2002-01-18 | Use of compositions containing pdgf-bb for promoting angiogenesis |
EP02714757A EP1355659A2 (en) | 2001-01-26 | 2002-01-18 | Use of compositions containing pdgf-bb for promoting angiogenesis |
AU2002247007A AU2002247007B2 (en) | 2001-01-26 | 2002-01-18 | Use of compositions containing PDGF-BB for promoting angiogenesis |
US10/198,917 US20030139333A1 (en) | 2002-01-18 | 2002-07-19 | Methods and compositions for promoting angiogenesis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26445701P | 2001-01-26 | 2001-01-26 | |
US60/264,457 | 2001-01-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002058718A2 true WO2002058718A2 (en) | 2002-08-01 |
WO2002058718A3 WO2002058718A3 (en) | 2003-04-17 |
Family
ID=23006154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/001666 WO2002058718A2 (en) | 2001-01-26 | 2002-01-18 | Use of compositions containing pdgf-bb for promoting angiogenesis |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1355659A2 (en) |
JP (1) | JP4434584B2 (en) |
AU (1) | AU2002247007B2 (en) |
CA (1) | CA2436076A1 (en) |
WO (1) | WO2002058718A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004533411A (en) * | 2001-01-26 | 2004-11-04 | カイロン コーポレイション | Unit doses of angiogenically effective FGF-2 and methods of use |
JP2005168654A (en) * | 2003-12-09 | 2005-06-30 | Kissei Pharmaceut Co Ltd | Growth factor-bonded low molecular weight modified heparin |
WO2007034320A3 (en) * | 2005-09-26 | 2007-10-04 | Proteins & Peptides Man | Pdgf amphiphilic polymer complex |
FR2914191A1 (en) * | 2007-03-29 | 2008-10-03 | Proteins & Peptides Man | ANGIOGENIC COMPOSITION |
WO2010035122A2 (en) * | 2008-09-26 | 2010-04-01 | Adocia | Complex consisting of polysaccharide and an hpb |
WO2010078624A1 (en) * | 2009-01-07 | 2010-07-15 | Vegenics Limited | Materials and methods for the treatment of hypertension |
WO2016147005A1 (en) * | 2015-03-19 | 2016-09-22 | Cell Therapy Limited | Composition comprising basic fibroblast growth factor (fgf-2) and platelet derived growth factor (pdgf) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5025646B2 (en) * | 2005-11-08 | 2012-09-12 | 公益財団法人先端医療振興財団 | Treatment method for ischemic heart disease |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990000060A1 (en) * | 1988-06-30 | 1990-01-11 | Collagen Corporation | Collagen wound healing matrices and process for their production |
WO1991016009A1 (en) * | 1990-04-17 | 1991-10-31 | Curative Technologies, Inc. | Coating prosthetic surfaces with mammalian cells |
US5128321A (en) * | 1986-08-13 | 1992-07-07 | Zymogenetics, Inc. | PDGF analogs and methods of use |
WO1994025056A2 (en) * | 1993-04-29 | 1994-11-10 | Washington University | Use of platelet-derived growth factor to improve collateral circulation |
WO1997012601A2 (en) * | 1995-10-06 | 1997-04-10 | Ethicon, Inc. | Gel formulations containing growth factors |
WO2000041732A1 (en) * | 1999-01-19 | 2000-07-20 | The Children's Hospital Of Philadelphia | Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof |
-
2002
- 2002-01-18 CA CA002436076A patent/CA2436076A1/en not_active Abandoned
- 2002-01-18 EP EP02714757A patent/EP1355659A2/en not_active Ceased
- 2002-01-18 AU AU2002247007A patent/AU2002247007B2/en not_active Ceased
- 2002-01-18 WO PCT/US2002/001666 patent/WO2002058718A2/en active Application Filing
- 2002-01-18 JP JP2002559052A patent/JP4434584B2/en not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5128321A (en) * | 1986-08-13 | 1992-07-07 | Zymogenetics, Inc. | PDGF analogs and methods of use |
WO1990000060A1 (en) * | 1988-06-30 | 1990-01-11 | Collagen Corporation | Collagen wound healing matrices and process for their production |
WO1991016009A1 (en) * | 1990-04-17 | 1991-10-31 | Curative Technologies, Inc. | Coating prosthetic surfaces with mammalian cells |
WO1994025056A2 (en) * | 1993-04-29 | 1994-11-10 | Washington University | Use of platelet-derived growth factor to improve collateral circulation |
WO1997012601A2 (en) * | 1995-10-06 | 1997-04-10 | Ethicon, Inc. | Gel formulations containing growth factors |
WO2000041732A1 (en) * | 1999-01-19 | 2000-07-20 | The Children's Hospital Of Philadelphia | Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof |
Non-Patent Citations (8)
Title |
---|
EDELMAN E.R. ET AL.: "Controlled and modulated release of basic fibroblast growth factor." BIOMATERIALS, vol. 12, no. 7, September 1991 (1991-09), pages 619-626, XP000226106 * |
FRANK K R ET AL: "CONTROLLED RELEASE OF BIOACTIVE GROWTH FACTORS FROM A BIODEGRADABLE DELIVERY SYSTEM" PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 11, no. 10, October 1994 (1994-10), page S88,ANBIOTEC2070 XP001068790 ISSN: 0724-8741 * |
KAWAI K ET AL: "Accelerated tissue regeneration through incorporation of basic fibroblast growth factor-impregnated gelatin microspheres into artificial dermis - targeted delivery systems" BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 21, no. 5, March 2000 (2000-03), pages 489-499, XP004185546 ISSN: 0142-9612 * |
LIECHTY K.W. ET AL.: "Adenoviral-mediated overexpression of platelet-derived growth factor-B corrects ischemic impaired wound healing." J. INVEST. DERMATOL., vol. 113, no. 3, September 1999 (1999-09), pages 375-383, XP002211469 * |
PARK Y J ET AL: "Controlled release of platelet-derived growth factor-BB from chondroitin sulfate-chitosan sponge for guided bone regeneration" JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 67, no. 2-3, July 2000 (2000-07), pages 385-394, XP004199184 ISSN: 0168-3659 * |
PARK Y.J.: "Controlled release of PDGF from porous poly(L-lactide) membranes for guided tissue regeneration." J. CONTROLLED RELEASE., vol. 51, 1998, pages 201-211, XP004113628 * |
STEED D L ET AL: "CLINICAL EVALUATION OF RECOMBINANT HUMAN PLATELET-DERIVED GROWTH FACTOR FOR THE TREATMENT OF LOWER EXTREMITY DIABETIC ULCERS" JOURNAL OF VASCULAR SURGERY, C.V. MOSBY CO., ST. LOUIS, MO, US, vol. 1, no. 21, January 1995 (1995-01), pages 71-81, XP001088899 ISSN: 0741-5214 * |
YLÄ-HERTTUALA S. AND MARTIN J.F.: "Cardiovascular gene therapy" LANCET, vol. 355, 15 January 2000 (2000-01-15), pages 213-222, XP002211470 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004533411A (en) * | 2001-01-26 | 2004-11-04 | カイロン コーポレイション | Unit doses of angiogenically effective FGF-2 and methods of use |
JP2005168654A (en) * | 2003-12-09 | 2005-06-30 | Kissei Pharmaceut Co Ltd | Growth factor-bonded low molecular weight modified heparin |
AU2006293613B2 (en) * | 2005-09-26 | 2012-05-17 | Adocia | PDGF amphiphilic polymer complex |
WO2007034320A3 (en) * | 2005-09-26 | 2007-10-04 | Proteins & Peptides Man | Pdgf amphiphilic polymer complex |
US8241620B2 (en) | 2005-09-26 | 2012-08-14 | Adocia | Complex polymere amphiphile-PDGF |
FR2914191A1 (en) * | 2007-03-29 | 2008-10-03 | Proteins & Peptides Man | ANGIOGENIC COMPOSITION |
WO2008120085A3 (en) * | 2007-03-29 | 2009-09-11 | Adocia | Angiogenic composition |
WO2008120085A2 (en) * | 2007-03-29 | 2008-10-09 | Adocia | Angiogenic composition |
WO2010035122A2 (en) * | 2008-09-26 | 2010-04-01 | Adocia | Complex consisting of polysaccharide and an hpb |
WO2010035122A3 (en) * | 2008-09-26 | 2011-05-05 | Adocia | Complex consisting of polysaccharide and an hpb |
US8367640B2 (en) | 2008-09-26 | 2013-02-05 | Adocia | Complex consisted of a polysaccharide and an HBP |
WO2010078624A1 (en) * | 2009-01-07 | 2010-07-15 | Vegenics Limited | Materials and methods for the treatment of hypertension |
WO2016147005A1 (en) * | 2015-03-19 | 2016-09-22 | Cell Therapy Limited | Composition comprising basic fibroblast growth factor (fgf-2) and platelet derived growth factor (pdgf) |
Also Published As
Publication number | Publication date |
---|---|
JP2005506279A (en) | 2005-03-03 |
JP4434584B2 (en) | 2010-03-17 |
CA2436076A1 (en) | 2002-08-01 |
EP1355659A2 (en) | 2003-10-29 |
WO2002058718A3 (en) | 2003-04-17 |
AU2002247007B2 (en) | 2006-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001268149B2 (en) | Methods and compounds for controlled release of recombinant parvovirus vectors | |
Winn et al. | Gene therapy approaches for modulating bone regeneration | |
ES2206342T3 (en) | MEDICAL DEVICE THAT INCLUDES A SYNTHETIC SURFACE THAT HAS NUCLEIC ACID FOR IN VIVO INDUCTION OF ITS ENDOTELIALIZATION. | |
US20030139333A1 (en) | Methods and compositions for promoting angiogenesis | |
US20080031923A1 (en) | Biologic Replacement for Fibrin Clot | |
US20020172663A1 (en) | Localized myocardial injection method for treating ischemic myocardium | |
JP2006524691A (en) | Genetic modification of targeted regions of the cardiac conduction system | |
CN1198675A (en) | Medicine comprising HGF gene | |
AU2002247007B2 (en) | Use of compositions containing PDGF-BB for promoting angiogenesis | |
US20080102059A1 (en) | Treatment for arthritis | |
AU772857B2 (en) | Method of inducing angiogenesis | |
AU2002247007A1 (en) | Use of compositions containing PDGF-BB for promoting angiogenesis | |
CN103638002A (en) | Encapsulated liver cell composition | |
WO1989007944A1 (en) | Device for site directed neovascularization and method for same | |
EA019099B1 (en) | Method for targeted transgene delivery in myocardium of a patient with myocardial ischemia | |
CN1630538A (en) | Stimulation of vascularization with VEGF-B | |
ES2434257T3 (en) | Non-polymeric hematopoietic cell clots for active agent delivery | |
JP2014218509A (en) | Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy | |
WO2001087312A1 (en) | Polyethylene glycol (peg) polymers for the promotion of angiogenesis | |
Vranckx et al. | 15 Gene Transfer of Growth Factors for Wound Repair | |
Wang et al. | In vitro circadian ANP secretion by gene transferring cells encapsulated in polycaprolactone tubes: gene chronotherapy | |
EP1948247A2 (en) | Compositions for coordinated vegf and pdgf expression, and methods of use | |
Davidson | 13 Gene Therapy of Wounds | |
WO2005086684A2 (en) | Method for modulating, regulating and/or stabilizing angiogenesis | |
EP1556494A2 (en) | Bicistronic vector encoding a vegf and an fgf, use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 10198917 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002714757 Country of ref document: EP Ref document number: 2436076 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002559052 Country of ref document: JP Ref document number: 2002247007 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2002714757 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |